To further assess the importance of CD8 T cells in SERT-mediated tumor control, we depleted CD8 T cells in Sert-WT mice challenged with B16-OVA melanoma, followed by FLX treatment (Figure 3J). The gene discussed is CD8A; the disease is melanoma.